Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06995177
ABSTRACT:
Compounds of formula (I) and pharmaceutically acceptable salts and esters thereof are active as inhibitors of hepatitis C virus NS3 protease. Consequently they are potentially useful in the treatment and prevention of hepatitis C virus infection and related conditions. In formula: (I) represents an aromatic or aliphatic carbocyclic ring and (n) is the total number of carbon atoms in the ring and is form 4 to 8.
REFERENCES:
patent: WO 99/38888 (1999-08-01), None
Ingallinella et al, “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products,” Biochemistry (1998), vol. 37, pp. 8906-8914.
CDC Updates Guidelines for Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings: http://www.aafp.org/afp/20030615/practice.html.
Paolo Ingallinella, et al.; Biochemistry; vol. 37(25); pp. 8906-8914; 1998.
Bianchi Elisabetta
Fattori Daniela
Ingallinella Paolo
Pessi Antonello
Camara Valerie J.
Campell Bruce R.
Heard Thomas S.
Istituto Di Ricerche Di Biologia Molecolare P Angeletti SpA
Walton Kenneth R.
LandOfFree
HCV NS3 protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HCV NS3 protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV NS3 protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665664